Current Price
Impact BioMedical, Inc. is an innovative biotechnology company focused on developing groundbreaking therapeutics and technologies to address critical healthcare challenges. Utilizing advanced research methodologies, the...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
Earnings estimates are not available for this company.
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | IImpact Bio... | IBO | $44.41M | 0.41 | 4.39 | 4,247.00% | -12,621.00% | 71.20% | 16.70% |
| 2. | RRallybio C... | RLYB | $88.03M | 3.41 | 0.95 | 6,177.00% | -5,051.00% | 34.50% | — |
| 3. | KKyntra Bio | KYNB | $13.93M | — | 80.40 | 3,969.00% | -1,089.00% | — | 36.50% |
| 4. | FFibroGen I... | FGEN | $39.28M | — | 53.83 | 2,599.00% | -499.10% | -1,016.00% | 775.00% |
| 5. | AAnaptysBio... | ANAB | $1.38B | 7.09 | 66.07 | 417.60% | 15.00% | -114.50% | -60.30% |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Dec 24 | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 | Sep 26 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0.01 | 0.02 | 0.01 | 0.01 | 0 | 0.02 |
COGS | 0.28 | 0.28 | 0.01 | 0 | 1.27 | 0.28 | 0 | 0.01 |
Gross Profit | -0.28 | -0.28 | -0 | 0.02 | -1.27 | -0.28 | 0 | 0.01 |
Gross Profit % | - | - | -57.14% | 94.44% | -18100% | -3971.43% | 66.67% | 71.43% |
| 26.23 | 0.73 | 1.15 | 0.01 | 0.46 | 2.01 | 0.7 | 0.66 | |
EBIT | -26.23 | -1.01 | -1.15 | 0.01 | -1.16 | -2.29 | -0.7 | -0.65 |
OPM % | - | - | -16471.43% | 27.78% | -16542.86% | -32700% | -23400% | -3085.71% |
Non-Operating Income | -0.87 | -0.27 | -13.2 | -1.48 | 3.81 | 0.01 | 0 | 0 |
PBT | -27.1 | -1.28 | -14.35 | -1.48 | 2.65 | -2.28 | -0.7 | -0.64 |
Income Tax | 0.03 | 0 | 0 | -0.01 | -2.58 | 0 | -0 | 0 |
Tax Rate % | -0.12% | - | - | 0.34% | -97.18% | -0.13% | 0.14% | -0.16% |
Net Income | -27.11 | -1.27 | -14.35 | -1.47 | 5.25 | -2.29 | -0.7 | -0.65 |
NPM % | - | - | -204942.86% | -8166.67% | 74928.57% | -32671.43% | -23300% | -3071.43% |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0.05 | 0.05 | 1.03 | 2.33 | 0.03 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.57 |
Gross Profit | 0 | 0 | 0 | 0 | 0 | 0.05 | 1.03 | 2.33 | -1.54 |
Gross Profit % | - | - | - | - | - | 100% | 100% | 100% | -4803.13% |
| 0.18 | 0.07 | 0.68 | 1.14 | 3.86 | 3.45 | 4.03 | 1.78 | 2.73 | |
EBIT | 0.06 | -0.03 | -0.68 | -1.14 | -3.83 | -3.4 | -4.03 | 0.55 | -4.27 |
OPM % | - | - | - | - | -7666.13% | -6808% | -391.07% | 23.67% | -13343.75% |
Non-Operating Income | 0 | 0 | -0.17 | 0 | -0.03 | -4.47 | -0.38 | -2.6 | -10.18 |
PBT | -0.41 | -0.1 | -0.85 | -1.14 | -3.87 | -7.88 | -4.41 | -2.05 | -14.45 |
Income Tax | 0 | 0 | 0.06 | -0.1 | 0.02 | -0.62 | 0 | 0 | -2.58 |
Tax Rate % | - | - | -6.96% | 9.14% | -0.39% | 7.88% | - | 0% | 17.85% |
Net Income | -0.41 | -0.1 | -0.59 | -0.76 | -3.87 | -7.05 | -4.34 | -2.05 | -11.84 |
NPM % | - | - | - | - | -7734.43% | -14102% | -420.98% | -88.01% | -36993.75% |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.39 | 0.05 | 0.2 | 0.1 | 0.05 | 0.14 | 0 | 0 | 2 | 0 | |
| 0 | 0 | 0 | 0 | 0.63 | 4.82 | 0.78 | 0 | 2 | 0 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0.28 | 0.29 | 0.02 | 0 | |
| 0 | 0.03 | 0 | 0.02 | 0.02 | 0.11 | 0.12 | 0.33 | 0.45 | 0.41 | |
| 0.02 | 0.24 | 0.01 | 0 | -0.63 | -1.08 | 45.32 | 44.01 | 15.83 | 16.99 | |
Total Assets | 0.41 | 0.32 | 0.22 | 0.12 | 0.07 | 3.99 | 46.5 | 44.63 | 20.29 | 17.41 |
| 0.4 | 0.6 | 0.6 | 0.62 | 0.7 | 13.79 | 0.07 | 0.01 | 0.01 | 0.1 | |
| 0 | -0.3 | -0.4 | -0.52 | -0.7 | -10.84 | 29.49 | 25.21 | 4.25 | 12.5 | |
| 0 | 0 | 0 | 0 | 0.06 | 0.41 | 9.99 | 12.07 | 8.88 | 0.62 | |
| 0 | 0 | 0 | 0.02 | 0.02 | 0.05 | 0.6 | 1.06 | 0.91 | 1.16 | |
| 0.01 | 0.03 | 0.02 | 0 | -0 | 0.59 | 3.23 | 3.23 | 3.27 | 0.07 | |
Total Liabilities | 0.41 | 0.32 | 0.22 | 0.12 | 0.07 | 3.99 | 43.39 | 41.59 | 17.31 | 14.46 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| -0.32 | -0.07 | -0.12 | -0 | -3.25 | -4.33 | -2.85 | -3.92 | -1.89 | |
| -0.23 | 0.23 | -0.03 | -0 | -0.04 | -2.09 | -0.01 | 0 | 0 | |
| 0.21 | 0 | 0.02 | 0 | 3.38 | 7.01 | 2.87 | 5.92 | -0.11 | |
Net CFNet Cash Flow | -0.34 | 0.15 | -0.13 | -0 | 0.09 | 0.58 | -0 | 2 | -2 |
FCFFree Cash Flow | -0.32 | -0.07 | -0.12 | -0 | -3.53 | -4.43 | -2.87 | -3.92 | -1.89 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | -117.5% | -39.9% | -404.2% | -1696.4% | -263.2% | -43.4% | -15.8% | -13.9% | -140.4% | |
| - | - | - | - | -11.36 | 0.14 | 0.34 | 0.48 | 2.08 | 0.05 | |
| 72.43 | 12.61 | 10.81 | 5.31 | 3.98 | 0.91 | 0.01 | 0.03 | 0.25 | 0.35 | |
| - | - | - | 0.00 | - | 0.02 | 0.00 | 0.02 | 0.07 | 0.00 | |
Cash Conversion | - | 0.78 | 0.73 | 0.21 | 0.00 | 0.84 | 0.61 | 0.66 | 1.91 | 0.16 |
Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| - | - | - | - | - | - | 0.0% | 1960.0% | 126.3% | -98.6% | |
| - | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.10 | -0.15 | -0.18 | -1.03 | |
| - | - | - | - | - | - | - | - | -9.70 | -0.51 | |
| - | 2.00 | 4.00 | 2.00 | 2.00 | 3.00 | 4.00 | 6.00 | 3.00 | 3.00 | |
| - | - | - | - | - | - | -3.96 | 14.93 | -1.78 | 48.22 | |
| - | 0.00 | 0.00 | 0.00 | - | 50.00 | 60.00 | 60.00 | 33.33 | 33.33 | |
| - | - | - | - | - | -77.3% | -141.0% | -4.2% | -0.9% | -369.9% |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns NYSE AMEX LISTED TEST STOCK FOR CTS CQS, from SEC filings
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Jun 2026 can still change as late 13F amendments arrive.
| % of shares outstanding | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | QoQ |
|---|---|---|---|---|---|---|---|---|---|
| 70.24% | 66.83% | 85.91% | 28.25% | 3.29% | 3.19% | 3.57% | 3.57% | 0.00 | |
ForeignForeign institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 |
USUS institutions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 |
Govt.Government & pensions | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00 |
Public | 29.76% | 33.17% | 14.09% | 71.75% | 96.71% | 96.81% | 96.43% | 96.43% | 0.00 |
No. of institutional holders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Month | Insiders | Shares sold | Value sold | Shares bought | Value bought | Awards, tax, gifts |
|---|---|---|---|---|---|---|
| 9 | — | — | — | — | 37,530 | |
| 1 | 906 | $1.7K | — | — | — | |
| 2 | 95,000 | $57.8K | — | — | — |
Form 4, filed within two business days of each trade. Sales and purchases are open-market; awards, tax withholding, gifts and option exercises are grouped. Amended filings are left out so a restated trade isn't counted twice.
| Settlement date | Short shares | Change | % of shares out | Days to cover | Relative size |
|---|---|---|---|---|---|
| 30 Oct 2026 | 24,619 | -6.4% | 0.02% | 1.15 | |
| 15 Oct 2026 | 26,292 | -12.9% | 0.02% | 2.05 | |
| 30 Sep 2026 | 30,169 | -94.3% | 0.03% | 1.98 | |
| 15 Sep 2026 | 526,986 | -2.1% | 0.49% | 1.00 | |
| 31 Aug 2026 | 538,182 | -1.5% | 0.50% | 19.26 | |
| 14 Aug 2026 | 546,651 | -1.5% | 0.51% | 13.20 | |
| 31 Jul 2026 | 554,915 | -0.4% | 0.51% | 27.06 | |
| 15 Jul 2026 | 557,404 | +0.2% | 0.52% | 10.01 | |
| 30 Jun 2026 | 556,491 | -10.4% | 0.52% | 7.38 | |
| 15 Jun 2026 | 621,006 | -17.2% | 0.58% | 6.43 | |
| 29 May 2026 | 750,055 | -4.3% | 0.70% | 21.70 | |
| 15 May 2026 | 783,895 | -22.5% | 0.73% | 13.65 | |
| 30 Apr 2026 | 1,011,901 | -16.5% | 0.94% | 10.74 | |
| 15 Apr 2026 | 1,212,039 | -36.7% | 1.12% | 8.00 | |
| 31 Mar 2026 | 1,915,023 | +45.3% | 1.78% | 2.15 | |
| 13 Mar 2026 | 1,317,647 | +765.2% | 1.22% | 1.00 | |
| 27 Feb 2026 | 152,299 | +8.0% | 0.14% | 3.56 | |
| 13 Feb 2026 | 141,078 | -41.0% | 0.13% | 2.51 | |
| 30 Jan 2026 | 238,997 | -17.0% | 0.22% | 4.85 | |
| 15 Jan 2026 | 287,957 | -13.1% | 0.27% | 5.91 | |
| 31 Dec 2025 | 331,314 | +293.6% | 0.31% | 1.38 | |
| 15 Dec 2025 | 84,165 | -14.8% | 0.08% | 1.00 | |
| 28 Nov 2025 | 98,739 | -35.0% | 0.09% | 1.47 | |
| 14 Nov 2025 | 151,978 | -1.2% | 0.14% | 1.25 |
FINRA consolidated short interest, reported twice a month for every US listing.
NYSE AMEX LISTED TEST STOCK FOR CTS CQS's SEC filings and earnings call transcripts
What recent news says about NYSE AMEX LISTED TEST STOCK FOR CTS CQS, scored for sentiment.